Aesthetic Medicine – July-August 2026

Summary

The new prevention era — longevity medicine, advanced diagnostics, and personalised health — anchors Aesthetic Medicine July-August 2026, alongside the human touch debate as AI becomes more embedded in the patient journey. Editor Kezia Parkins features an interview with Ahmed El Houssieny on governance, business, education, and why caution still matters.

The issue examines the shift from reactive treatment to proactive prevention in medical aesthetics. The cover feature "The New Prevention Era" argues that longevity medicine — including advanced biomarker testing, epigenetic clocks, and personalised supplementation — is reshaping the sector's focus from surface correction to systemic health. "The Human Touch" explores what is lost as AI tools handle consultation intake, treatment planning, and follow-up communication.

Dr Ahmed El Houssieny discusses his approach to governance in a fast-moving sector, the business case for conservative treatment protocols, and the role of education in maintaining standards. Product spotlights cover SCULPTRA, ESTYME, and Restylane Skinboosters. The issue also includes regulatory updates, clinical safety guidance, and a UK subscription offer: print GBP 44 annually, digital GBP 10.

—————

Content Guide

▸ Cover Feature

p. Cover · The New Prevention Era
Longevity medicine is driving a sector shift from reactive aesthetics to proactive prevention. The article covers advanced biomarker testing, epigenetic age clocks, and personalised supplement protocols that clinicians are integrating into aesthetic practice. The biomarker reference range table lists six key markers — telomere length, DNA methylation age, C-reactive protein, HbA1c, vitamin D, and homocysteine — with optimal ranges for aesthetic patients seeking preventative treatment.

▸ Practice & Ethics

p. Cover · The Human Touch
As AI-powered consultation tools and automated treatment-planning software enter aesthetic clinics, the article examines what is lost when the patient journey becomes digitised. Clinicians interviewed report that AI intake forms miss non-verbal cues that a nurse or doctor would catch in a face-to-face conversation. The article recommends a hybrid model: AI for administrative triage, human assessment for clinical decisions.

p. Cover · Getting to Know Ahmed El Houssieny
Dr Ahmed El Houssieny discusses the governance framework he applies to his practice, why he chooses conservative treatment protocols over aggressive dosing, and how he structures his continuing education. He names three specific business metrics he tracks monthly: conversion rate, complication rate, and patient-return interval. The interview includes his treatment-decision algorithm for first-time filler patients.

▸ Products & Technology

SCULPTRA
The poly-L-lactic acid biostimulator is profiled with updated protocols for face and body applications. The article includes the reconstitution time and dilution ratios for different treatment areas. The manufacturer reports a 90 percent patient satisfaction rate at 12 months post-treatment across 500 surveyed patients.

ESTYME
The transdermal delivery system for active ingredients is presented with clinical data on absorption rates compared to topical application. The study data shows a 400 percent increase in active-ingredient delivery depth using the ESTYME iontophoresis platform versus passive topical application.

Restylane Skinboosters
The HA skin booster range is profiled for microinjection protocols targeting skin hydration and elasticity. The article includes a practitioner guide to injection depth and volume per pass for the face, neck, and décolletage.

▸ Regulation & Safety

Regulatory Update
Recent changes to UK aesthetic medicine regulation are summarised, including the ongoing consultation on mandatory licensing for non-surgical procedures. The timeline shows that the Health and Care Act 2022 licensing powers have not yet been implemented by any local authority in England. Wales and Scotland remain unregulated.

Clinical Safety Guidance
Updated protocols for managing vascular occlusion, anaphylaxis, and infection in the aesthetic clinic. The emergency algorithm is reproduced with drug dosages and administration routes for adrenaline, hyaluronidase, and broad-spectrum antibiotics. The algorithm is designed to be laminated and kept in every treatment room.

—————

Editor's Take

Aesthetic Medicine July-August 2026 is a transitional issue — the prevention-era concept is timely but the articles are more introductory than instructive. The Ahmed El Houssieny interview offers the most practical value with specific metrics and decision algorithms. Weakest parts: the product spotlights read as manufacturer-provided content with no critical comparison between competing products. The regulatory update is useful but covers the same ground as the previous issue — no new legislation has passed. This issue suits the clinic owner considering adding longevity services to their menu.

Strengths
• Biomarker reference ranges for preventative aesthetic assessment
• Ahmed El Houssieny treatment-decision algorithm
• Vascular occlusion emergency algorithm with drug dosages

Weaknesses
• Product spotlights lack critical comparison
• Regulatory update repeats prior issue content

Verdict: Selective read — Useful as a thought-starter for prevention-oriented practice.